Due to tumor immune tolerance and the heterogeneity of the tumor microenvironment, several preclinical risks need to be addressed for the application of CXCL12 treatment and CXCR4+ B cell adoptive transfer. This evidence concerns the gene CXCL12 and neoplasm.